Drug Profile

BLX 0871

Alternative Names: BLX-0871; MLX-0800; MLX-0871

Latest Information Update: 18 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Biolexis Therapeutics
Class Antihyperglycaemics; Obesity therapies; Small molecules
Mechanism of Action AMP activated protein kinase stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Obesity; Type 2 diabetes mellitus

Most Recent Events

12 Jun 2025 Pharmacodynamics data from a preclinical study in Obesity released by Biolexis Therapeutics
12 Jun 2025 Biolexis Therapeutics plans a first in human phase I trial for Type 2 diabetes mellitus and obesity (PO) in August 2025
12 Jun 2025 Biolexis Therapeutics plans a phase I trial for Obesity (Combination therapy) in the second quarter of 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com